Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT03289299 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

ASCENT
Start date: May 25, 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.

NCT ID: NCT03236428 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Start date: November 24, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab

NCT ID: NCT02960555 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Start date: February 8, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.

NCT ID: NCT02916771 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

NCT ID: NCT02886065 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Citarinostat (CC-96241) - PVX-410

NCT ID: NCT02603887 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Start date: July 20, 2016
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02415413 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

NCT ID: NCT02316106 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Start date: May 20, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

NCT ID: NCT01572480 Active, not recruiting - Multiple Myeloma Clinical Trials

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Start date: May 29, 2012
Phase: Phase 2
Study type: Interventional

Background: - Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The current standard of care for SMM is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for SMM itself. One possible treatment involves a combination of cancer treatment drugs. - Lenalidomide is a drug that may help reduce or prevent the growth of cancer cells. Dexamethasone is a steroid that is often given with other anti-cancer drugs. These two drugs are an approved treatment for multiple myeloma that has not responded to at least one other treatment. Carfilzomib is an experimental drug that has been effective in treating multiple myeloma. Researchers want to combine these three drugs to see if they are a safe and effective treatment for SMM. Objectives: - To see if carfilzomib, lenalidomide, and dexamethasone are a safe and effective treatment for smoldering multiple myeloma. Eligibility: - Individuals at least 18 years of age who have SMM that is likely to progress to multiple myeloma. Design: - Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and baseline bone marrow scans. Bone marrow samples will also be collected. - Participants will have eight 28-day cycles of treatment with the three study drugs. The drugs will be given as tablets or as infusions. Treatment will be monitored with frequent blood tests and study visits. - After the first four cycles, participants who are eligible for a stem cell transplant will have their stem cells collected and stored for future use. - At the end of eight cycles, participants whose disease has not progressed will have up to 12 more cycles of treatment with lenalidomide tablets alone.

NCT ID: NCT01177527 Active, not recruiting - Multiple Myeloma Clinical Trials

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Start date: December 2009
Phase:
Study type: Observational

The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases. The investigators will also study the tumor cells at the level of the participant's genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes.